Holli Dilks on Molecular Profiling
Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.
Clinical trial eligibility is often dependent on molecular status, but determining which patients should undergo molecular profiling and when can be challenging, said Dilks.
The National Comprehensive Cancer Network (NCCN) offers guideline that can help oncologists determine at which stage of disease patients should be profiled.
Reaching out to pharmaceutical partners to find out the eligibility criteria for patients to enroll can also help oncologists determine when molecular profiling is necessary.